Clinical investigation of new medicinal products for the treatment of acute coronary syndrome

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CHMP/760125/2016
Published20/09/2017
Effective from01/03/2018
KeywordsAcute coronary syndrome, STE-ACS, NSTE-ACS
DescriptionThis guideline replaces 'Points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) without persistent ST segment elevation' (CPMP/EWP/570/98) and 'Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (STEMI)' (CPMP/EWP/967/01).


Document history

First version

Current version

 

Adopted guideline

 

Overview of comments


Draft guideline
 

Concept paper

In operation: 01/03/2018 - present

 

Published: 26/09/2017
 

Published: 27/04/2016
 

Published: 15/10/2014

Superseded documentAdopted guidelineIn operation: 01/09/2000 - 01/03/2018


Related content


How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings
    

Tell us more